Organogenesis HoldingsSTU:2PQ +0.95%67 Quick Ratio is 3.16 as of Mar. 2026, which is 34% above its 10-year median of 2.36. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.74 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 994 Drug Manufacturers companies, Organogenesis Holdings ranks better than 77.36% on this metric.
Organogenesis Holdings has a quick ratio of 3.16. It generally indicates good short-term financial strength.
The historical rank and industry rank for Organogenesis Holdings's Quick Ratio or its related term are showing as below:
STU:2PQ'
s Quick Ratio Range Over the Past 10 Years
Min: 0.03 Med: 2.36 Max: 7.01
Current: 3.16
During the past 11 years, Organogenesis Holdings's highest Quick Ratio was 7.01. The lowest was 0.03. And the median was 2.36.
STU:2PQ's Quick Ratio is ranked better than 77.36% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs STU:2PQ: 3.16
Organogenesis Holdings (STU:2PQ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Organogenesis Holdings Quick Ratio Related Terms
Organogenesis Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2PQ vs TKNO, AKBA, SIGA: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Organogenesis Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (STU:2PQ) has a Quick Ratio of 3.16 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Organogenesis Holdings and its competitors. This is 34% above median its historical median of 2.36. Over the past decade, Organogenesis Holdings' Quick Ratio has ranged from 0.03 to 7.01. According to the industry distribution chart, Organogenesis Holdings ranks #225 out of 994 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Organogenesis Holdings' Quick Ratio too high?
Organogenesis Holdings' current Quick Ratio of 3.16 is 34% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 7.01. The Drug Manufacturers industry median Quick Ratio is 1.45. Organogenesis Holdings' value of 3.16 is 117.9% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #225 out of 994 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Quick Ratio compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #225 out of 994 companies for Quick Ratio. This places Organogenesis Holdings in the top 23% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Organogenesis Holdings' value of 3.16 is 117.9% above this benchmark. Historically, Organogenesis Holdings' own Quick Ratio has ranged from 0.03 to 7.01 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 1.45, Organogenesis Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Quick Ratio of 3.16 is 117.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Quick Ratio is 3.16, which is 34% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.74, compared to a current price of €2.12 — trading 22.6% below its estimated fair value. The current Quick Ratio is 3.16, which is 34% above median its 10-year median of 2.36 and 117.9% above the Drug Manufacturers industry median of 1.45. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Quick Ratio is 3.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.12 is trading 22.6% below its estimated GF Value™ of €2.74.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for STU:2PQ:
Quick Ratio: 3.16 (34% above median its 10-year median of 2.36)
GF Value™: €2.74 vs. price of €2.12 (22.6% below fair value)
Industry Position: 117.9% above the Drug Manufacturers median (#225 of 994)
No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for STU:2PQ
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2PQ has been successfully added to your 
